HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase II trial of neoadjuvant chemotherapy with XELOX plus bevacizumab for locally advanced rectal cancer.

Abstract
In Western countries, the standard treatment for locally advanced rectal cancer is preoperative chemoradiotherapy followed by total mesorectal excision. On the other hand, in Japan, treatment results without radiotherapy are by no means inferior; therefore, extrapolation of results of preoperative treatment in Western countries to Japan is controversial. We consider that survival may be improved by preoperative treatment with new anticancer agents as they are expected not only to decrease the local recurrence rate but also to prevent distant metastases. We are conducting a multicentre Phase II study to evaluate the safety and efficacy of neoadjuvant chemotherapy using XELOX plus bevacizumab without radiotherapy in patients with locally advanced rectal cancer. The primary endpoint of the study is treatment compliance. Secondary endpoints are overall survival, disease-free survival, local recurrence-free survival, objective response rate, R0 resection rate and adverse events. Thirty patients are required for this study.
AuthorsKeisuke Uehara, Seiji Ishiguro, Eiji Sakamoto, Atsuyuki Maeda, Masaya Inoue, Yuichiro Tojima, Satoshi Kobayashi, Naoki Omiya, Naoki Ishizuka, Akimasa Nakao, Hidemi Goto, Masato Nagino
JournalJapanese journal of clinical oncology (Jpn J Clin Oncol) Vol. 41 Issue 8 Pg. 1041-4 (Aug 2011) ISSN: 1465-3621 [Electronic] England
PMID21803876 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Oxaloacetates
  • Deoxycytidine
  • Bevacizumab
  • Capecitabine
  • Fluorouracil
Topics
  • Adenocarcinoma (drug therapy, surgery)
  • Antibodies, Monoclonal (administration & dosage)
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects, therapeutic use)
  • Bevacizumab
  • Capecitabine
  • Deoxycytidine (administration & dosage, analogs & derivatives)
  • Disease-Free Survival
  • Fluorouracil (administration & dosage, analogs & derivatives)
  • Humans
  • Neoadjuvant Therapy
  • Oxaloacetates
  • Rectal Neoplasms (drug therapy, surgery)
  • Research Design
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: